MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Experimental rotenone model

X. Djakhangir, A. Ziyoda (Tashkent, Uzbekistan)

Meeting: 2018 International Congress

Abstract Number: 1684

Keywords: Parkinsonism

Session Information

Date: Monday, October 8, 2018

Session Title: Parkinson's Disease: Pathophysiology

Session Time: 1:15pm-2:45pm

Location: Hall 3FG

Objective: To evaluat rotene model of parkinsonian syndrome in rats.

Background: Rotenone is of highly lipophilic substances that can freely enter hematoencephalic barrier through and biological membranes. The mechanism of action of rotenone as mechanism MPTP actions associated with mitochondrial respiratory chain. The advantage of the method rotenone modeling Parkinson’s disease is ability rotenone to provoke dopaminergic neurodegeneration, most similar in its symptoms and molecular biological characteristics to those of Parkinson’s disease.

Methods: In order to simulate Parkinson’s disease, rotenone is used primarily on cellular structures and embryological studies. In adult animals, primarily rats, rotenone used less frequently because of its low chemical stability in animal tissues and body fluids. rotenone administered by infusion, by micropumps, preferably intravenously.

Results: Behavior of animals studied at 3, 6 and 9 days of the experiment. Used a series of tests for the detection of extrapyramidal disorders, as well as test apomorphine verticalization. Apomorphine is administered at a dose of 1 mg / kg subcutaneously 5 min assess vertical activity, and after 10 min – postural instability. Also used unilateral introduction of rotenone (12 .mu.g in 0.5 .mu.l with Dimexidum a rate of 0.1 .mu.l / min.) in «medial forebrain bundle» by coordinates (AP: +0,2; L: ± 1,8; DV: 8 mm) stereotactic atlas.

Conclusions: Intranigralnoe single unilateral introduction of rotenone in small doses on today is available as one of the adequate models of parcinsonian syndrome of rats, which reproduces lengthy neurochemical and neuropathological changes similar to the changes in Parkinson diseases in the nigrostriatal system. Application of this method rotenone administration (doses of 3, 6 and 12 .mu.g) caused no change in peripheral organs for 4 weeks follow-up.

References: Winkler C., Kirik D., Bjorklund A., Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson’s disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis.

To cite this abstract in AMA style:

X. Djakhangir, A. Ziyoda. Experimental rotenone model [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/experimental-rotenone-model/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/experimental-rotenone-model/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley